Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 3:16 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1489–1512 of 5,141 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: AIDS (Acquired Immunodeficiency Syndrome) Clear all

Conditions: HIV Infections
Interventions: Treatment regimen change; Behavioral
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2005
U.S. locations: 23
States / cities: Menlo Park, California • Stanford, California • Torrance, California + 15 more

Conditions: HIV Infections
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Up to 24 Months
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2005
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Mycobacterium Avium-intracellulare Infection, HIV Infections
Interventions: Nelfinavir mesylate, Nevirapine, Azithromycin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2001
U.S. locations: 26
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 17 more

Conditions: Viral Infections
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV Infections
Interventions: Zidovudine, Didanosine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years and older
Enrollment: 750 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 70
States / cities: Los Angeles, California • Palo Alto, California • San Diego, California + 41 more

Conditions: Substance-Related Disorders, HIV
Interventions: Contingency Management; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Cryptosporidiosis, HIV Infections
Interventions: Paromomycin sulfate; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1996
U.S. locations: 14
States / cities: Los Angeles, California • Miami, Florida • Chicago, Illinois + 7 more

Conditions: HIV, ICL, Healthy Volunteers
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 386 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1994
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Infections, Human Immunodeficiency Virus and Hepatitis
Interventions: GSK1265744 Na Salt Tablets, GSK1265744 Free Acid Nanomilled Capsules, GSK1265744 Free Acid Micronized Capsules; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: CD4 Lymphocytopenia, Idiopathic CD4 Positive T Lymphocytopenia
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1992 – 2003
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Latent Tuberculosis, HIV Infections
Interventions: T-Spot.TB test; Other
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years to 75 Years
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Staten Island, New York

Conditions: HIV Infections
Interventions: MedSignals™; Device
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: Santa Barbara, California

Conditions: HIV Infections
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 14
States / cities: Birmingham, Alabama • San Diego, California • Denver, Colorado + 10 more

Conditions: HIV Infections
Interventions: rAd35 Env A, rAd5 Env A, rAd5 Env B; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 180 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2016
U.S. locations: 8
States / cities: Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 4 more

Conditions: HIV Infections
Interventions: Not listed
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years to 69 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Sacramento, California

Conditions: HIV Infections
Interventions: rgp120/HIV-1MN, rgp120/HIV-1 SF-2, gp160 Vaccine (MicroGeneSys); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 1 Month to 18 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1996
U.S. locations: 33
States / cities: Long Beach, California • Los Angeles, California • Oakland, California + 21 more

Conditions: HIV Infections, Hemophilia A
Interventions: Indinavir sulfate, Lamivudine, Stavudine, Zidovudine, Zalcitabine, Didanosine; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 16 Years and older · Male only
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 7
States / cities: San Francisco, California • Washington D.C., District of Columbia • Atlanta, Georgia + 4 more

Conditions: HIV Infections
Interventions: HE2000; Drug
Lead sponsor: Harbor Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 6
States / cities: Palm Springs, California • Palo Alto, California • San Francisco, California + 3 more

Conditions: HIV Infections
Interventions: Nevirapine, Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 1 Day and older
Enrollment: 1,500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 2004
U.S. locations: 1
States / cities: Research Triangle Park, North Carolina

Conditions: HIV Infections, Hemophilia A
Interventions: Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1989
U.S. locations: 2
States / cities: Buffalo, New York • Rochester, New York

Conditions: Sexually Transmitted Diseases, HIV Infections
Interventions: CenteringPregnancy, CenteringPregnancyPlus, Usual care; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 14 Years to 25 Years · Female only
Enrollment: 1,047 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2008
U.S. locations: 2
States / cities: New Haven, Connecticut • Atlanta, Georgia

Conditions: HIV Infections
Interventions: CPT31, Placebo; Drug
Lead sponsor: Navigen, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Tuberculosis, HIV Infections
Interventions: rifabutin, isoniazid, efavirenz; Drug
Lead sponsor: National Center for Research Resources (NCRR); NIH
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Acquired Immunodeficiency Syndrome, Burning Mouth Syndrome, HIV Infection
Interventions: Thalidomide; Drug
Lead sponsor: National Institute of Dental and Craniofacial Research (NIDCR); NIH
Eligibility: Not listed
Enrollment: 110 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1996 – 2004
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

Effects of Changing HIV Therapy at Lower Versus Higher Viral Loads

Immune Function of Infants With HIV

A Study to Learn More About MAC Disease and the Use of Anti-HIV Drugs in Patients With Advanced HIV Infection

Specimens From Normal Controls

A Phase II Efficacy Study Comparing 2',3'-Dideoxyinosine (ddI) (BMY-40900) and Zidovudine Therapy of Patients With HIV Infection Who Have Been on Long Term Zidovudine Treatment

Expression of Stress Markers During Meth Treatment (EXPRESS+)

A Double-Blind, Placebo-Controlled Trial of Paromomycin for Treatment of Cryptosporidiosis in Patients With Advanced HIV Disease and CD4 Counts Under 150 Cells/mm3

Tissue Biopsy and Imaging Studies in HIV-Infected Patients

Relative Bioavailability Study of GSK1265744 Formulations

Evaluation of HIV-Negative Patients With Low CD4+ T Lymphocyte Counts

Is Tuberculin Skin Testing Effective in Screening for Latent Tuberculosis in Patients With HIV?

An Electronic Pillbox for People With HIV

The Effects of Illnesses on HIV Levels in the Body

Evaluating Heterologous-Insert Prime-Boost HIV Vaccine Regimens in HIV-Uninfected Adults

Impact of Antiretroviral Therapy on Cardiac Biomarkers

A Placebo-Controlled, Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant Envelope Proteins of HIV-1 gp160 and gp120 in Children >= 1 Month Old With Asymptomatic HIV Infection

Effect of Indinavir Plus Two Other Anti-HIV Drugs on Blood Clotting in HIV-Positive Males With Hemophilia

A Study on the Safety and Anti-HIV Activity of HE2000 in HIV-Infected Patients on Salvage Therapy

Effectiveness of AZT and Nevirapine in Preventing HIV Transmission From Ugandan Mothers to Their Newborns

Safety and Effectiveness of Azidothymidine (AZT) in HIV-Positive Patients With Hemophilia

Group Prenatal Care for Reducing the Risk of STDs in Pregnant Young Women

A Clinical Study of the HIV Drug CPT31 in Healthy Volunteers

Intensive Pharmacokinetics of the Nelfinavir-Rifabutin Interaction in Patients With HIV-Related Tuberculosis Treated With a Rifabutin-Based Regimen

Thalidomide to Treat Oral Lesions in HIV-Infected Patients